BRIEF-FDA Approves GSK's Jemperli As First Immunotherapy For MSI-H/DMMR Rectal Cancer

2

Oct 19 (Reuters) – GSK plc: * GSK PLC – JEMPERLI APPROVED IN MSI-H/DMMR RECTAL CANCER * GSK – NO DISEASE RECURRENCES REPORTED AMONG RESPONDERS AFTER TWO-YEAR MEDIAN FOLLOW UP * GSK – FDA APPROVES

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)